Article Details
Retrieved on: 2021-06-23 14:37:30
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
Roche's lampalizumab, an antibody fragment against factor D, another alternative pathway activator, was discontinued after failing in phase 3 in 2017.
Article found on: www.evaluate.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here